ENANTA PHARMACEUTICALS INC (ENTA)
Health Care · Biopharmaceuticals / Antiviral therapeutics · NASDAQ
Enanta is a biopharmaceutical company generating revenue primarily from royalties on marketed antiviral and other therapeutic drugs.
What ENANTA PHARMACEUTICALS INC does
Enanta Pharmaceuticals is a biopharmaceutical company that develops and commercializes antiviral medications and other therapeutic treatments. The company generates substantially all of its revenue from royalty payments on sales of marketed pharmaceutical products. Enanta is currently unprofitable despite achieving revenue growth, with most operating expenses dedicated to research and development efforts. The company maintains a portfolio of marketed therapies and continues to invest in pipeline advancement.
Themes: ["Antiviral therapeutics"]
Fundamentals
- Price$14.25 as of 2026-07-09 close
- Market cap$421M as of 2026-07-10
- 1-year return+99.9% as of 2026-07-09 close
- Net margin-89.6% as of 2026-07-10
- ROE-64.0% as of 2026-07-10
- Debt / equity1.12 as of 2026-07-10
- Revenue growth (YoY)+7.4% as of 2026-07-10
- Revenue CAGR (3y)-8.8% SEC XBRL
- Beta0.91 as of 2026-07-10
Key risks (from latest filing)
["Company is significantly unprofitable with negative net margin of -89.56%, dependent on continued royalty revenue growth to fund operations"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.